Mark Cuban's Cost Plus Drugs targets rare disease market with custom n-of-1 therapies

Mark Cuban's Cost Plus Drugs, known for low-cost generics, is expanding into rare disease treatments.

The company has dedicated part of its new manufacturing plant to producing custom "n-of-1" therapies, which are individualized gene-based medicines designed for a single patient’s genetic mutation.

Early shipments to the Dallas facility included DNA-like molecules created with partners in California and the Netherlands, aimed at addressing a rare neurodegenerative condition and a muscle-wasting disease.

Cuban says the initiative is meant to lower the cost and increase access for patients with ultra-rare disorders, a market traditionally dominated by high-price specialty drugs.